Centinel Spine (New York) has completed the initial cases with three different implant portfolios within its FLX platform of integrated interbody and non-integrated interbody fusion devices. FLX devices are 3D-printed, all-titanium implants with a combination of solid and porous radiolucent sections designed to reduce mechanical stiffness and improve visibility, as compared to solid titanium implants. The […]
From Cytosorbents opening a new U.S. manufacturing facility to DyAnsys received FDA clearance for a wearable to treat opioid withdrawals, here are seven medtech stories we missed this week but thought were still worth mentioning. 1. Cytosorbents opens new U.S. manufacturing facility CytoSorbents announced in a June 12 press release that it has opened a new […]
Fresh from its acquisition of Johnson & Johnson (NYSE:JNJ) subsidiary DePuy Synthes’ Prodisc assets, Centinel Spine last week reported raising more than $132 million. In the waning days of 2017, Centinel it closed its acquisition of DePuy’s Prodisc-C, Prodisc-L, Prodisc-C Vivo, Prodisc-C Nova, Prodisc-O and Discover cervical and lumbar artificial disc systems. Although the purchase price remained undisclosed, Centinel said at […]
Centinel Spine said last week that it closed its acquisition of Johnson & Johnson (NYSE:JNJ) subsidiary DePuy Synthes’ Prodisc assets for an undisclosed amount. The deal covers DePuy’s Prodisc-C, Prodisc-L, Prodisc-C Vivo, Prodisc-C Nova, Prodisc-O and Discover cervical and lumbar artificial disc systems. The Prodisc-C and Prodisc-L are the only two products which have approval in the U.S. Centinel plans to […]
Centinel Spine has agreed to acquire Johnson & Johnson (NYSE:JNJ) subsidiary DePuy Synthes’ Prodisc assets for an undisclosed amount, according to an OrthoWorld report. In the deal, DePuy is offloading its Prodisc-C, Prodisc-L, Prodisc-C Vivo, Prodisc-C Nova, Prodisc-O and Discover cervical and lumbar artificial disc systems to Centinel Spine, according to the report. The Prodisc-C and Prodisc-L […]
Centinel Spine said yesterday it won Australian Therapeutic Goods Administration clearance for its Stalif L no-profile lateral lumbar integrated interbody system. Centinel Spine touts the Stalif L as the only lateral device to offer a no-profile, compressive lag fixation device with proprietary anti-backout technology and 12-degrees of lordosis, as well as a large chamber for bone […]
Centinel Spine said today it won FDA 510(k) clearance for its Altos posterior cervical thoracic stabilization system with indications for use in lateral masses of the cervical spine or pedicles of the cervical-thoracic spine. The West Chester, Penn.-based company said the 1st surgical implantation of the system was performed earlier this month at Las Vegas’ Western […]
Centinel Spine today claimed it won the 1st multi-level indication for an interbody fusion device in the cervical spine, saying the FDA OK’d its Stalif C and Stalif C-Ti devices for then procedures. “This is a valuable indication given the high incidence of multilevel degenerative disc disease in the cervical spine. We are excited to be the 1st company to receive […]
MassDevice keeps a close eye on public medical device companies, tracking their quarterly sales and earnings reports. For the most recent filings, check out our Earnings Roundup, where we collect each quarter’s reports.
Here’s a quick rundown of a few releases over the past few days:
A British court handed Paradigm BioDevices Inc. a win in its contract dispute with Centinel Spine LLC subsidiary Surgicraft Ltd., ruling that Surgicraft must pony up a kill fee for terminating a deal with Paradigm in 2008.
Rockland, Mass.-based Paradigm sued Surgicraft in 2008, after the Redditch, England-based firm abruptly canceled Paradigm’s exclusive deal to distribute Surgicraft’s Stalif TT spinal fusion device. Centinel, which is owned by New York-based orthopedics hedge fund Viscogliosi Brothers LLC, acquired Surgicraft in 2008.